TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced or metastatic cancer~* Other available therapies have failed to cure the cancer~* The cancer that has no proven effective therapy~* The cancer can be biopsied (depending on the tumor type and/or the dose of drug received, tumor biopsies may be required)~* Able to swallow capsules~Exclusion Criteria:~* Have active cancer in the brain or spinal cord~* Have an active infection of any kind (fungal, viral, or bacterial)~* Have a cancer of the blood~* Are pregnant or breastfeeding~* Have some types of eye problems or impairments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 Dose Escalation (Type: EXPERIMENTAL): LY3009120 50 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
- Cohort 2 Dose Escalation (Type: EXPERIMENTAL): LY3009120 100 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
- Cohort 3 Dose Escalation (Type: EXPERIMENTAL): LY3009120 200 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
- Cohort 4 Dose Escalation (Type: EXPERIMENTAL): LY3009120 400 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
- Cohort 5 Dose Escalation (Type: EXPERIMENTAL): LY3009120 500 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
- Cohort 6 Dose Escalation (Type: EXPERIMENTAL): LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
- Cohort A Dose Confirmation (Type: EXPERIMENTAL): LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
- Cohort B Dose Confirmation (Type: EXPERIMENTAL): LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
- Cohort C Dose Confirmation (Type: EXPERIMENTAL): LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Bosentan in Myocardium Metabolism and Perfusion Measured by 18F-FDG and 82Rb PET/CT on PAH and CTEPH

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with chronic PAH (PH group 1 Dana Point / stages 2 à 4 according to NYHA classification, defined by a mean arterial pulmonary pressure \>25 millimeter of mercury (mmHg) at rest, an occlusion arterial pulmonary pressure \<15 millimeter of mercury (mmHg) and vascular pulmonary resistance \>240 dyn.s.cm-5 for which a treatment with bosentan is indicated Or Patients with CTEPH not candidate for a pulmonary endarterectomy or patient with residual CTEPH after pulmonary endarterectomy (PH group 4 Dana Point / stages 2 to 4 according to NYHA classification) and for which a treatment with bosentan is indicated~* Indication to perform a right heart catheterization in the context of PAH suspected during cardiac ultrasound~* Age from 18 to 80 years old, male and female~* Karnofsky index ≥80%~* Informed consent signed~Exclusion Criteria:~* Patients with PAH stages 2,3 or 5 of Dana Point~* Patients with a contra-indication to adenosine including severe uncontrolled asthma, severe uncontrolled chronic obstructive pulmonary disease, 2nd or 3rd degree atrioventricular block without pacemaker,~* Patients with a contraindication to Bosentan, i.e :hypersensibility to the product, hepatic failure Child Pugh B or C, aminotransferases \>3 times normal value (N),association with cyclosporine A or glibenclamide~* Pregnancy, female of child-bearing potential not using any acceptable contraceptive method, breastfeeding~* Atrial fibrillation (Ventricular Ejection Fraction (VEF) not evaluable at echography)~* Karnofsky index \<80%~* Impossibility to obtain informed consent signed~* Left cardiopathies that can be responsible of post-capillar hypertension~* Involvement in another clinical study with an unregistered drug within 30 days prior to this specific study and during the entire course of the study~* Inability to comply with study procedures (linguistic problem, psychiatric problems, dementia, confusional state)~* Known or suspected non compliance drug or alcohol abuse~* Left heart assessment : diastolic and systolic function and valvular structures to exclude a cardiac pathology

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Non-operative Versus Operative Management of Olecranon Fractures in the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥75 years~* Minimal, moderate or severe fragmentation of the olecranon~* Within two weeks of olecranon fracture~Exclusion Criteria:~* Patients unable to give informed consent~* Associated fractures to the coronoid, radial head and/or distal humerus~* Associated ligamentous injury, dislocation or subluxation~* Open fractures

- Gender: ALL
- Minimum Age: 75 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non-operative (Type: OTHER): Patients in the non-operative arm will be managed conservatively using a sling, or an above elbow lightweight cast if problems with pain, for 10-14 days post injury. Patients will then be allowed to mobilise as able.
- Operative (Type: OTHER): Patients in this arm will be managed operatively for their olecranon fracture using either tension band wiring or plate fixation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Local Application of Vancomycin Powder in Grade I-IIIA Open Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Skeletally mature patients ≥18 years of age~* Acute Gustilo-Anderson Type I-IIIA open fracture~* Fracture is deemed primarily closable at initial surgery~* Likely to follow-up with surgeon until fracture is healed~* Ability to understand and agree to Informed Consent~Exclusion Criteria:~* Patients \<18 years of age~* Gustilo-Anderson Type IIIB and IIIC open fractures~* Open fractures requiring multiple operations (i.e. for repeat surgical debridement or staged bone grafting of critical segmental defects)~* Delayed presentation of open fracture~* Pre-existing systemic infection requiring antibiotic therapy~* Allergy to Vancomycin~* Open fracture at the site of a previous fracture or surgical site~* Current skin infection, chronic wounds or known systemic infection~* Unlikely to follow-up until fracture is healed~* Unable to understand or agree to Informed Consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vancomycin Powder (Type: EXPERIMENTAL): If the patient randomizes to the experimental group (vancomycin powder), the patient will receive open fracture care identical to the control group except that, prior to closure, 1 gram of vancomycin powder will be applied locally to the open fracture bed. The traumatic and surgical wounds will be closed over a sterile drain and dressed, and the extremity will be immobilized.
- Standard Treatment (Type: NO_INTERVENTION): If the patient randomizes to the control group (standard treatment), the patient will receive irrigation and debridement of the fracture site and surrounding soft tissues. The fracture will then be stabilized in standard fashion determined by fracture personality. Once stabilized, a sterile drain will be placed in the open fracture bed and the traumatic and surgical wounds will be closed and dressed. The extremity will then be immobilized.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intermediate Normal Versus High Normal Oxygen Levels in the Emergency Department for Severe Traumatic Brain Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patient ≥18 years~* Glasgow Coma Scale ≤ 8~* Non-penetrating traumatic brain injury~* Intubated patient~Exclusion Criteria:~* Age \<18 years~* Lack of intention to admit to the intensive care unit~* Moribund patient expected to die within 24 hours~* Expected need for mechanical ventilation \< 24 hours~* Time interval from intubation to group allocation more than 60 minutes~* Penetrating traumatic brain injury~* Pregnancy~* Lack of equipoise of the treating clinician~* Lack of informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intermediate normal oxygen (Type: ACTIVE_COMPARATOR): For the intermediate normal oxygen group, an oxygen saturation by pulse oximetry (SpO2) of 95-97% will be recommended in the light of the Improving Oxygen Therapy in Acute-illness (IOTA) meta-analysis. The acceptable lower limit of PaO2 will be set to 80 mmHg according to a recent consensus of experts endorsed by the European Society of Intensive Care Medicine. The lower-limit and higher-limit monitor alarm for SpO2 will be set at 94% and 98%, respectively.~In case that the emergency department of a study site uses ventilators, which allow for only two options of FiO2 titration (namely, air mix and FiO2 of 1.0), then the intermediate normal oxygen group should receive air mix.
- High normal oxygen (Type: ACTIVE_COMPARATOR): For the high normal oxygen group, an oxygen saturation by pulse oximetry (SpO2) of 99-100% will be recommended. The lower-limit monitor alarm for SpO2 will be set at 98%. No upper alarm limit for SpO2 will be set.~In case that the emergency department of a study site uses ventilators, which allow for only two options of FiO2 titration (namely, air mix and FiO2 of 1.0), then the high normal oxygen group should receive FiO2 of 1.0.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Self-administration of Medication During Hospitalization on Medication Safety, Adherence, and Patient Satisfaction in Dutch Hospitals

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients (≥ 16 years old) admitted to the ward who use medication or will be using medication at home after hospital discharge and are able to administer (part of) this medication themselves~Exclusion Criteria:~* Not providing informed consent~* The use of a medication box without original medication boxes~* The use of medication pre-packaged by automated dispensing system~* The need of homecare support to administer medication~* The need of an informal caretaker to help with medication administration~* Admitted from a nursing home and medication is under supervision of the staff~* Not understanding the Dutch language, written or spoken~* The subject is not capable of managing SAM (due to mental or physical state)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard care (Type: NO_INTERVENTION): Based on an (electronic) order placed by a physician, nurses collect medication and provide patients with the ordered medication in a timely matter. Nurses document the administration either in an electronic medical record or on paper.
- Self-administration of medication (SAM) (Type: EXPERIMENTAL): During SAM medication is stocked at the patient's bedside. When medication is scheduled to be administered, patients collect those form their own stock, administer, and document the administration by themselves. Once daily nurses check whether patients succeeded in administration for all prescriptions of the last 24 hours. Each day, patients are qualified for SAM. In the case patients do not meet the criteria of SAM, they will be excluded from SAM.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Role of a Silicone Prosthesis to Prevent Airway Obstruction Recurrence in Lung Cancers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years~* non-small cell lung cancer,~* inoperable and location : tracheal, carinal, main bronchus right or left, or intermediate trunk.~* TNM stage known and oncological treatment later determined~* central initial intrinsic bronchial obstruction \> 50%.~* resection of tumor with endoscopy, to obtain after therapeutic bronchoscopy a diameter \> 50% normal diameter of bronchial segment achieved.~* Tumoral segment fully recoverable by a stent~* Written consent, free and informed~* Patient affiliated or who is entitled to to a social security scheme.~Exclusion Criteria:~* against-indication for general anesthesia.~* Patient with one lung not working beyond the stenosis~* Patient under guardianship~* Pregnancy~* 12 months follow-up impossible

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- trachea-bronchial stent (Novatech) (Type: EXPERIMENTAL): None
- control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:Male and female patients ages 18 years and older who are referred to the Division of Gastroenterology at the Dallas VA Medical Center for the evaluation of heartburn that is refractory to PPI therapy~Exclusion Criteria:~1. Patients unwilling or unable to provide informed consent.~2. Allergy to lansoprazole.~3. Patients taking warfarin.~4. Coagulopathy that precludes safe biopsy of the esophagus.~5. Comorbidity that precludes safe participation in the study.~6. Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females~2. Age 18 years or greater~3. Scheduled to undergo liver biopsy with ultrasound guidance at a performance site~Exclusion Criteria:~1. Liver biopsy is not intended to obtain tissue from a specific lesion~2. Known or suspected cardiac shunt~3. History of hypersensitivity to any active or inactive ingredients in Lumason

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- biopsy with Lumason (Type: EXPERIMENTAL): liver biopsy performed with prior contrast enhancement with Lumason 60.7Mg Powder for Injection (experimental method)
- biopsy with placebos (Type: PLACEBO_COMPARATOR): liver biopsy performed without prior contrast enhancement (standard method)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Post-menopausal women~* Asymptomatic microscopic hematuria (three or more red blood cells per high powered field on a single urine microscopy) in the absence of urinary tract infection.~Exclusion Criteria:~* Known urologic disease~* Presence of gross hematuria~* Presence of indwelling urologic foreign body (foley catheter, ureteral stent)~* Inability to obtain intravenous contrast CT scan (elevated creatinine, severe contrast allergy)~* History of pelvic irradiation or malignancy~* Not a candidate for vaginal estrogen~  * Allergy to vaginal estrogen~ * Current or prior diagnosis of breast or endometrial cancer~ * History of deep vein thrombosis/pulmonary embolus~ * Hypercoagulable state

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Premarin vaginal cream (Type: EXPERIMENTAL): Premarin vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks.
- Placebo vaginal cream (Type: PLACEBO_COMPARATOR): Placebo vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Memory Phenotype and PD-1 Inhibition Response in Oral Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed histologically proven locoregional oral squamous cell carcinoma (OSCC) without evidence of distant metastases. OSCC includes the subsites of oral tongue, floor of mouth, gingiva, retromolar trigone and buccal mucosa OR~Recurrent or persistent histologically proven locoregional OSCC that was initially treated with surgery alone.~* must be eligible for surgical resection~* greater than 18 years of age~Exclusion Criteria:~* prior immunotherapy or treatment with another anti PD-1 agent besides nivolumab~* prior chemotherapy including cetuximab or radiation therapy~* concomitant malignancies except cutaneous squamous cell carcinoma or basal cell carcinoma~* unresectable primary tumor or regional disease or distant metastases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Received Nivolumab (Type: None): None
- Nivolumab Naive (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of MM by International Myeloma Working Group Criteria~* In first or second complete or partial remission or stable refractory but not actively progressing myeloma according to the classifications provided by The Center for International Blood \& Marrow Transplant Research~* Received at least 2 cycles of lenalidomide therapy~* Patients with MM scheduled to undergo stem cell harvest for possible allogeneic stem cell transplant (ASCT)~* At least 2 weeks since last exposure to lenalidomide~* Eastern Cooperative Oncology Group performance status of 0 or 1~* Prior to the start of mobilization:~  * white blood cell count \>/= 2.5 x 10\^9/L~ * absolute neutrophil count \>/= 1.2 x 10\^9/L~ * platelet count \>/=100 x 10\^9/L~ * creatinine clearance \>/= 30mL/minute~* If childbearing potential, must either agree to complete abstinence from heterosexual intercourse or effective means of contraception during stem cell mobilization; female patients will undergo pregnancy test prior to stem cell mobilization therapy~Exclusion Criteria:~* Had prior autologous or allogeneic transplantation~* Received pegfilgrastim within 3 weeks or G-CSF within 14 days of first dose of G-CSF for mobilization~* Failed previous hematopoietic stem cell collections or collection attempts~* Received radiation therapy to the pelvic area~* Received lenalidomide within 2 weeks of first dose of G-CSF for mobilization~* Had received experimental therapy within 4 weeks of enrolling in study~* Current or prior history of other malignancies, excluding basal cell carcinoma of the skin

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: ACTIVE_COMPARATOR): Patients receive G-CSF SC QD on days 1-4.
- Arm II (Type: EXPERIMENTAL): Patients receive G-CSF SC QD on days 1-4 and plerixafor SC QD on days 4-8.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues